Cormedix Inc (CRMD) 2.89 $CRMD CorMedix Inc. to
Post# of 273254
Posted On: 09/21/2016 7:18:41 AM
Cormedix Inc (CRMD) 2.89 $CRMD
CorMedix Inc. to Present at Multiple Investor and Industry Conferences
ACCESSWIRE - Tue Sep 20, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / September 20, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, announced today that its executives have been invited to speak at upcoming scientific, investor and industry conferences.
CRMD: 2.89 (+0.25)
CorMedix, Inc. Announces Signing of an Agreement with POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium), to Develop CRMD-005, a Proprietary Formulation of Taurolidine, for Rare Orphan Pediatric Tumors
ACCESSWIRE - Thu Sep 15, 7:06AM CDT
BEDMINSTER, NJ / ACCESSWIRE / September 15, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, and POETIC, The Pediatric Oncology Experimental Therapeutics Investigators Consortium, a group of 10 top tier academic medical centers, developing new promising pediatric cancer therapies are pleased to announce a joint development agreement focused on the oncologic applications of CRMD-005, a proprietary formulation of Taurolidine, as a potential treatment for rare orphan pediatric tumors, including neuroblastoma and osteosarcoma.
CRMD: 2.89 (+0.25)
CorMedix Inc. to Present at 2016 Rodman & Renshaw 18th Annual Global Investment Conference
ACCESSWIRE - Tue Sep 06, 7:31AM CDT
BEDMINSTER, NJ / ACCESSWIRE / September 6, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, announced today that chief executive officer Randy Milby will present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference, to be held September 11-13, 2016, at the Lotte New York Palace Hotel in New York City.
CRMD: 2.89 (+0.25)
CorMedix Inc. Invited to Present at Two Upcoming Scientific Conferences
ACCESSWIRE - Tue Aug 16, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / August 16, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, announced today that its executives have been invited to speak at two upcoming scientific and industry conferences. Chief executive officer Randy Milby will present at the 2016 World Anti-Microbial Resistance Congress and chief scientific officer Antony Pfaffle will participate on a panel at the Anti-Infectives Rx Conference.
CRMD: 2.89 (+0.25)
CorMedix (CRMD) Shows Strength: Stock Moves Up 24.8%
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:15AM CDT
CorMedix, Inc. (CRMD) shares rose almost 25% in the last trading session.
CRMD: 2.89 (+0.25), ANIK: 47.59 (+0.10)
CorMedix Inc. Reports Second Quarter 2016 Financial Results and Provides Business Updates
Marketwired - Fri Aug 05, 7:05AM CDT
Conference Call Today at 9:00 a.m. Eastern Time
CRMD: 2.89 (+0.25)
CorMedix Inc. to Report Second Quarter 2016 Financial Results
ACCESSWIRE - Tue Aug 02, 7:05AM CDT
Conference Call to be held Friday, August 5, 2016, at 9:00 a.m. Eastern Time
CRMD: 2.89 (+0.25)
CorMedix Inc. Announces Publication of Pharmacoeconomic Study that Highlights the Clinical and Economic Need for Products that Can Prevent Catheter-Related Bloodstream Infections
ACCESSWIRE - Mon Jun 13, 7:31AM CDT
Data Published in the Journal of Critical Care Supports the Potential of Neutrolin® as a Non-antibiotic Antimicrobial Solution
CRMD: 2.89 (+0.25)
CorMedix Inc. to Present at 2016 Marcum MicroCap Conference
ACCESSWIRE - Thu May 26, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 26, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that its Chief Executive Officer, Randy Milby, will present at The 2016 Marcum MicroCap Conference being held at the Grand Hyatt New York in New York City.
CRMD: 2.89 (+0.25)
CorMedix Inc. Presented Post-Market Clinical Utility Data from Neutrolin(R) Usage Monitoring Program at 53rd Joint Congress of the European Renal Association - European Dialysis and Transplant Association
ACCESSWIRE - Mon May 23, 8:15AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 23, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today Dr. Christoph Wanner, Professor of Medicine and Director of Nephrology at the University of Wurzburg, delivered an oral presentation titled, "A Novel Taurolidine Containing Catheter Lock Solution (CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study" at the 53rd ERA-EDTA Congress in Vienna, Austria.
CRMD: 2.89 (+0.25)
CorMedix Inc. Announces Publication of New Pharmacoeconomic Data Demonstrating Cost of Catheter-Related Infections at the ISPOR 21st Annual International Meeting
ACCESSWIRE - Wed May 18, 7:05AM CDT
21st Annual International Society for Pharmacoeconomics and Outcomes Research Meeting to be held May 21-25 in Washington, DC
CRMD: 2.89 (+0.25)
CorMedix Inc. to Ring New York Stock Exchange Opening Bell May 18, 2016
ACCESSWIRE - Mon May 16, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 16, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that its management team is scheduled to visit the New York Stock Exchange (NYSE) on May 18, 2016, to ring the NYSE Opening Bell®.
CRMD: 2.89 (+0.25)
CorMedix Inc. Reports First Quarter 2016 Financial Results
ACCESSWIRE - Wed May 11, 7:05AM CDT
Conference Call Today at 9:00 a.m. Eastern Time
CRMD: 2.89 (+0.25)
CorMedix Inc. Announces Agreement with NanoProteagen for its Proprietary Nanoparticle Technology, NanoPro(TM), in Combination with CRMD-005 for Pediatric Neuroblastoma
ACCESSWIRE - Wed May 11, 6:31AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 11, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has entered into two exclusive research licensing agreements with NanoProteagen, a biopharmaceutical company developing novel therapeutics against undruggable targets in immuno-oncology. Financial terms were not disclosed. Under the agreements, the two companies will use NanoProteagen's proprietary nanoparticle technology, NanoPro™, to test the feasibility of a novel combination therapy consisting of CRMD-005, a proprietary formulation of taurolidine, and vincristine, a standard of care cytotoxic chemotherapy agent, to a neuroblastoma tumor. Pediatric neuroblastoma is a pediatric orphan disease with an underserved need. CorMedix also was granted an option to obtain an exclusive worldwide license to the technology developed under the agreements.
CRMD: 2.89 (+0.25)
CorMedix Inc. to Report First Quarter 2016 Financial Results
ACCESSWIRE - Fri May 06, 7:05AM CDT
Conference Call to be held Wednesday, May 11, 2016, at 9 a.m. Eastern Time
CRMD: 2.89 (+0.25)
CorMedix Announces Publication of Neutrolin(R) Data to be Presented at the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases
ACCESSWIRE - Thu May 05, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 5, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today publication of a clinical abstract highlighting key data from the Company's landmark post-approval surveillance study of Neutrolin®. The abstract, titled, "A Novel Taurolidine Containing Catheter Lock Solution (CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection And Thrombosis in Hemodialysis Patients Enrolled In a Post-Approval Surveillance Study," is now available online in advance of CorMedix's poster presentation at the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases, to be held May 4-7, 2016, in Dubai, United Arab Emirates.
CRMD: 2.89 (+0.25)
CorMedix to Present Data from Landmark Post-Approval Surveillance Study at National Kidney Foundation(R) 2016 Spring Clinical Meetings
ACCESSWIRE - Thu Apr 21, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / April 21, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that a clinical abstract highlighting data from the Company's landmark post-approval surveillance study will be presented as a poster during the National Kidney Foundation® 2016 Spring Clinical Meetings, held April 27 - May 1, 2016, in Boston, Massachusetts. The abstract, titled, "A Novel Taurolidine Containing Catheter Lock Solution (CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study," has also been accepted for publication in the peer-reviewed American Journal of Kidney Diseases.
CRMD: 2.89 (+0.25)
CorMedix to Present at the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases
ACCESSWIRE - Tue Apr 19, 7:40AM CDT
BEDMINSTER, NJ / ACCESSWIRE / April 19, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that a clinical abstract, titled "A Novel Taurolidine Containing Catheter Lock Solution (CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection And Thrombosis in Hemodialysis Patients Enrolled In a Post-Approval Surveillance Study" highlighting key data from the Company's landmark post-approval surveillance study will be presented as a poster during the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases, to be held May 4-7 2016 in Dubai, United Arab Emirates.
CRMD: 2.89 (+0.25)
CorMedix (CRMD) Worth Watching: Stock Soars 19.9%
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:00AM CDT
CorMedix (CRMD) was a big mover last session with its surging almost 20% on the day.
CRMD: 2.89 (+0.25), GILD: 81.78 (+2.79)
CorMedix Inc. to Present at Multiple Investor and Industry Conferences
ACCESSWIRE - Tue Sep 20, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / September 20, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, announced today that its executives have been invited to speak at upcoming scientific, investor and industry conferences.
CRMD: 2.89 (+0.25)
CorMedix, Inc. Announces Signing of an Agreement with POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium), to Develop CRMD-005, a Proprietary Formulation of Taurolidine, for Rare Orphan Pediatric Tumors
ACCESSWIRE - Thu Sep 15, 7:06AM CDT
BEDMINSTER, NJ / ACCESSWIRE / September 15, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, and POETIC, The Pediatric Oncology Experimental Therapeutics Investigators Consortium, a group of 10 top tier academic medical centers, developing new promising pediatric cancer therapies are pleased to announce a joint development agreement focused on the oncologic applications of CRMD-005, a proprietary formulation of Taurolidine, as a potential treatment for rare orphan pediatric tumors, including neuroblastoma and osteosarcoma.
CRMD: 2.89 (+0.25)
CorMedix Inc. to Present at 2016 Rodman & Renshaw 18th Annual Global Investment Conference
ACCESSWIRE - Tue Sep 06, 7:31AM CDT
BEDMINSTER, NJ / ACCESSWIRE / September 6, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, announced today that chief executive officer Randy Milby will present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference, to be held September 11-13, 2016, at the Lotte New York Palace Hotel in New York City.
CRMD: 2.89 (+0.25)
CorMedix Inc. Invited to Present at Two Upcoming Scientific Conferences
ACCESSWIRE - Tue Aug 16, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / August 16, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, announced today that its executives have been invited to speak at two upcoming scientific and industry conferences. Chief executive officer Randy Milby will present at the 2016 World Anti-Microbial Resistance Congress and chief scientific officer Antony Pfaffle will participate on a panel at the Anti-Infectives Rx Conference.
CRMD: 2.89 (+0.25)
CorMedix (CRMD) Shows Strength: Stock Moves Up 24.8%
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:15AM CDT
CorMedix, Inc. (CRMD) shares rose almost 25% in the last trading session.
CRMD: 2.89 (+0.25), ANIK: 47.59 (+0.10)
CorMedix Inc. Reports Second Quarter 2016 Financial Results and Provides Business Updates
Marketwired - Fri Aug 05, 7:05AM CDT
Conference Call Today at 9:00 a.m. Eastern Time
CRMD: 2.89 (+0.25)
CorMedix Inc. to Report Second Quarter 2016 Financial Results
ACCESSWIRE - Tue Aug 02, 7:05AM CDT
Conference Call to be held Friday, August 5, 2016, at 9:00 a.m. Eastern Time
CRMD: 2.89 (+0.25)
CorMedix Inc. Announces Publication of Pharmacoeconomic Study that Highlights the Clinical and Economic Need for Products that Can Prevent Catheter-Related Bloodstream Infections
ACCESSWIRE - Mon Jun 13, 7:31AM CDT
Data Published in the Journal of Critical Care Supports the Potential of Neutrolin® as a Non-antibiotic Antimicrobial Solution
CRMD: 2.89 (+0.25)
CorMedix Inc. to Present at 2016 Marcum MicroCap Conference
ACCESSWIRE - Thu May 26, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 26, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that its Chief Executive Officer, Randy Milby, will present at The 2016 Marcum MicroCap Conference being held at the Grand Hyatt New York in New York City.
CRMD: 2.89 (+0.25)
CorMedix Inc. Presented Post-Market Clinical Utility Data from Neutrolin(R) Usage Monitoring Program at 53rd Joint Congress of the European Renal Association - European Dialysis and Transplant Association
ACCESSWIRE - Mon May 23, 8:15AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 23, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today Dr. Christoph Wanner, Professor of Medicine and Director of Nephrology at the University of Wurzburg, delivered an oral presentation titled, "A Novel Taurolidine Containing Catheter Lock Solution (CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study" at the 53rd ERA-EDTA Congress in Vienna, Austria.
CRMD: 2.89 (+0.25)
CorMedix Inc. Announces Publication of New Pharmacoeconomic Data Demonstrating Cost of Catheter-Related Infections at the ISPOR 21st Annual International Meeting
ACCESSWIRE - Wed May 18, 7:05AM CDT
21st Annual International Society for Pharmacoeconomics and Outcomes Research Meeting to be held May 21-25 in Washington, DC
CRMD: 2.89 (+0.25)
CorMedix Inc. to Ring New York Stock Exchange Opening Bell May 18, 2016
ACCESSWIRE - Mon May 16, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 16, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that its management team is scheduled to visit the New York Stock Exchange (NYSE) on May 18, 2016, to ring the NYSE Opening Bell®.
CRMD: 2.89 (+0.25)
CorMedix Inc. Reports First Quarter 2016 Financial Results
ACCESSWIRE - Wed May 11, 7:05AM CDT
Conference Call Today at 9:00 a.m. Eastern Time
CRMD: 2.89 (+0.25)
CorMedix Inc. Announces Agreement with NanoProteagen for its Proprietary Nanoparticle Technology, NanoPro(TM), in Combination with CRMD-005 for Pediatric Neuroblastoma
ACCESSWIRE - Wed May 11, 6:31AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 11, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has entered into two exclusive research licensing agreements with NanoProteagen, a biopharmaceutical company developing novel therapeutics against undruggable targets in immuno-oncology. Financial terms were not disclosed. Under the agreements, the two companies will use NanoProteagen's proprietary nanoparticle technology, NanoPro™, to test the feasibility of a novel combination therapy consisting of CRMD-005, a proprietary formulation of taurolidine, and vincristine, a standard of care cytotoxic chemotherapy agent, to a neuroblastoma tumor. Pediatric neuroblastoma is a pediatric orphan disease with an underserved need. CorMedix also was granted an option to obtain an exclusive worldwide license to the technology developed under the agreements.
CRMD: 2.89 (+0.25)
CorMedix Inc. to Report First Quarter 2016 Financial Results
ACCESSWIRE - Fri May 06, 7:05AM CDT
Conference Call to be held Wednesday, May 11, 2016, at 9 a.m. Eastern Time
CRMD: 2.89 (+0.25)
CorMedix Announces Publication of Neutrolin(R) Data to be Presented at the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases
ACCESSWIRE - Thu May 05, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / May 5, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today publication of a clinical abstract highlighting key data from the Company's landmark post-approval surveillance study of Neutrolin®. The abstract, titled, "A Novel Taurolidine Containing Catheter Lock Solution (CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection And Thrombosis in Hemodialysis Patients Enrolled In a Post-Approval Surveillance Study," is now available online in advance of CorMedix's poster presentation at the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases, to be held May 4-7, 2016, in Dubai, United Arab Emirates.
CRMD: 2.89 (+0.25)
CorMedix to Present Data from Landmark Post-Approval Surveillance Study at National Kidney Foundation(R) 2016 Spring Clinical Meetings
ACCESSWIRE - Thu Apr 21, 7:05AM CDT
BEDMINSTER, NJ / ACCESSWIRE / April 21, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that a clinical abstract highlighting data from the Company's landmark post-approval surveillance study will be presented as a poster during the National Kidney Foundation® 2016 Spring Clinical Meetings, held April 27 - May 1, 2016, in Boston, Massachusetts. The abstract, titled, "A Novel Taurolidine Containing Catheter Lock Solution (CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study," has also been accepted for publication in the peer-reviewed American Journal of Kidney Diseases.
CRMD: 2.89 (+0.25)
CorMedix to Present at the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases
ACCESSWIRE - Tue Apr 19, 7:40AM CDT
BEDMINSTER, NJ / ACCESSWIRE / April 19, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that a clinical abstract, titled "A Novel Taurolidine Containing Catheter Lock Solution (CLS) Without Reported Antimicrobial Resistance, Reduces the Rates of Infection And Thrombosis in Hemodialysis Patients Enrolled In a Post-Approval Surveillance Study" highlighting key data from the Company's landmark post-approval surveillance study will be presented as a poster during the 1st Gulf Congress of Clinical Microbiology and Infectious Diseases, to be held May 4-7 2016 in Dubai, United Arab Emirates.
CRMD: 2.89 (+0.25)
CorMedix (CRMD) Worth Watching: Stock Soars 19.9%
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:00AM CDT
CorMedix (CRMD) was a big mover last session with its surging almost 20% on the day.
CRMD: 2.89 (+0.25), GILD: 81.78 (+2.79)
(0)
(0)Scroll down for more posts ▼